Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004994666 | SCV005459467 | likely pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-09-28 | criteria provided, single submitter | clinical testing | The c.7907+1dupG variant results from a duplication of one nucleotide at position 7907+1 and involves the canonical splice donor site after coding exon 53 of the NF1 gene. This variant has been observed in at least one individual with a personal and/or family history that is consistent with neurofibromatosis type 1 (Ambry internal data). The canonical splice donor site is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |